📊 AURA Key Takeaways
Investment Thesis
Aura Biosciences is a pre-revenue biotech company with significant cash burn (-$64.3M operating cash flow) and no commercial revenue generation. While the company maintains strong liquidity with $47.6M cash and low leverage, the current burn rate at existing cash levels suggests limited runway without additional financing or achieving major clinical milestones. The absence of revenue combined with substantial operating losses and negative ROE/ROA indicates the company is in early-stage development with substantial execution risk.
AURA Strengths
- Strong liquidity position with $47.6M cash and 9.04x current ratio providing near-term financial flexibility
- Zero debt burden with minimal financial leverage, reducing refinancing risk
- Reasonable equity base of $156.7M providing capital cushion for development activities
AURA Risks
- No revenue generation with significant operating losses of -$85.6M indicating company is pre-commercial
- Severe cash burn of -$64.3M annually suggests limited runway of approximately 9 months at current burn rates without additional financing
- Biotech development risk: No evidence of approved products or positive clinical trial outcomes; success depends entirely on R&D execution and regulatory approval
Key Metrics to Watch
- Cash runway and path to profitability or next major financing event
- Clinical trial progress and regulatory milestones for lead programs
- Operating cash burn rate trends and any revenue-generating product approvals
AURA Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 9.04x current ratio provides a solid financial cushion.
AURA Profitability Ratios
AURA vs Healthcare Sector
How Aura Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AURA Balance Sheet & Liquidity
AURA 5-Year Financial Trend
5-Year Trend Summary: Aura Biosciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.93 indicates the company is currently unprofitable.
AURA Growth Metrics (YoY)
AURA Capital Allocation
AURA SEC Filings
Access official SEC EDGAR filings for Aura Biosciences, Inc. (CIK: 0001501796)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AURA
What is the AI rating for AURA?
Aura Biosciences, Inc. (AURA) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AURA's key strengths?
Strong liquidity position with $47.6M cash and 9.04x current ratio providing near-term financial flexibility. Zero debt burden with minimal financial leverage, reducing refinancing risk.
What are the risks of investing in AURA?
No revenue generation with significant operating losses of -$85.6M indicating company is pre-commercial. Severe cash burn of -$64.3M annually suggests limited runway of approximately 9 months at current burn rates without additional financing.
What is AURA's revenue and growth?
Aura Biosciences, Inc. reported revenue of N/A.
Does AURA pay dividends?
Aura Biosciences, Inc. does not currently pay dividends.
Where can I find AURA SEC filings?
Official SEC filings for Aura Biosciences, Inc. (CIK: 0001501796) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AURA's EPS?
Aura Biosciences, Inc. has a diluted EPS of $-1.39.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.